Last reviewed · How we verify

Triostat — Competitive Intelligence Brief

Triostat (LIOTHYRONINE) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: l-Triiodothyronine. Area: Oncology.

marketed l-Triiodothyronine Thyroid hormone receptor alpha Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Triostat (LIOTHYRONINE) — Pfizer. Triostat works by mimicking the natural thyroid hormone, l-Triiodothyronine, to stimulate the thyroid hormone receptor alpha.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Triostat TARGET LIOTHYRONINE Pfizer marketed l-Triiodothyronine Thyroid hormone receptor alpha 1956-01-01
Liothyronine and Levothyroxine Liothyronine and Levothyroxine National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) marketed Thyroid hormone replacement Thyroid hormone receptor alpha and beta (TRα, TRβ)
LT3 (liothyronine) LT3 (liothyronine) M. Medici phase 3 Thyroid hormone replacement Thyroid hormone receptor alpha (TRα), Thyroid hormone receptor beta (TRβ)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (l-Triiodothyronine class)

  1. Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Triostat — Competitive Intelligence Brief. https://druglandscape.com/ci/liothyronine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: